Nanobiotix (NASDAQ:NBTX) Price Target Cut to $8.00 by Analysts at Guggenheim

Nanobiotix (NASDAQ:NBTX) had its price target lowered by Guggenheim from $12.00 to $8.00 in a research report sent to investors on Friday,Benzinga reports. Guggenheim currently has a buy rating on the stock.

Separately, UBS Group raised shares of Nanobiotix to a “hold” rating in a research report on Monday, February 17th.

Nanobiotix Stock Performance

NBTX opened at $3.27 on Friday. Nanobiotix has a 1-year low of $2.76 and a 1-year high of $7.51. The company’s fifty day moving average price is $3.59 and its two-hundred day moving average price is $3.80.

Hedge Funds Weigh In On Nanobiotix

Hedge funds have recently bought and sold shares of the company. OLD Mission Capital LLC bought a new position in shares of Nanobiotix during the fourth quarter valued at about $139,000. Jane Street Group LLC bought a new position in shares of Nanobiotix during the 4th quarter worth approximately $73,000. Millennium Management LLC purchased a new position in shares of Nanobiotix in the 4th quarter worth approximately $39,000. Finally, Geode Capital Management LLC bought a new position in shares of Nanobiotix in the fourth quarter valued at approximately $29,000. 38.81% of the stock is owned by hedge funds and other institutional investors.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.